文献速递眼底病与葡萄膜炎

玻璃体内地塞米松植入剂治疗视网膜色素变性相关囊样黄斑水肿

INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA-RELATED CYSTOID MACULAR EDEMA.
PubMed 文献 · Retina · 2018-01-01

多中心回顾性病例系列纳入34例患者45眼视网膜色素变性合并囊样黄斑水肿,接受玻璃体内地塞米松植入剂治疗。首次注射后第3个月,平均最佳矫正视力从0.61±0.38(20/81)改善至0.37±0.16(20/47)(P=0.012),平均黄斑中心厚度从506±288 μm降至311.7±71.6 μm(P<0.001),平均眼压从15.7±2.3 mmHg升高至19.8±11.0 mmHg(P=0.01)。约半数眼最佳矫正视力改善维持至4个月,多次注射疗效持久,7眼出现有视觉意义的白内障。

要点

  • 首次注射后第3个月,平均最佳矫正视力从0.61±0.38(20/81)改善至0.37±0.16(20/47)(P=0.012)。
  • 平均黄斑中心厚度从506±288 μm降至311.7±71.6 μm(P<0.001),平均眼压从15.7±2.3 mmHg升至19.8±11.0 mmHg(P=0.01)。
  • 14眼接受多次注射(再注射1-7次),平均间隔6个月,疗效持久,7眼出现有视觉意义的白内障。

核心结论

  • 约半数眼最佳矫正视力改善维持至4个月,获益最明显者为人工晶状体眼、对类固醇无反应、初始黄斑中心厚度大及荧光素渗漏明显者。

研究设计与样本

  • 多中心回顾性病例系列,纳入34例患者45眼视网膜色素变性合并囊样黄斑水肿,接受玻璃体内地塞米松植入剂治疗。
  • 主要结局指标为LogMAR最佳矫正视力和黄斑中心厚度,统计采用Wilcoxon符号秩检验的双尾比较。

主要发现

  • 患者平均年龄32.7岁(范围16-57岁),平均随访15.5±13.0个月。
  • 首次注射后第3个月,平均最佳矫正视力从0.61±0.38(20/81)改善至0.37±0.16(20/47)(P=0.012)。
  • 首次注射后第3个月,平均黄斑中心厚度从506±288 μm降至311.7±71.6 μm(P<0.001)。
  • 首次注射后第3个月,平均眼压从15.7±2.3 mmHg升高至19.8±11.0 mmHg(P=0.01)。
  • 14眼接受多次注射(再注射1-7次),平均间隔6个月,多次注射疗效持久,7眼出现有视觉意义的白内障。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. METHODS: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. RESULTS: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (μm) decreased from 506 ± 288 μm to 311.7 ± 71.6 μm (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. CONCLUSION: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Mansour AM, Sheheitli H, Kucukerdonmez C, et al. INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA-RELATED CYSTOID MACULAR EDEMA. Retina. 2018. PMID: 28221257. doi:10.1097/IAE.0000000000001542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。